MA41742B1 - Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers. - Google Patents

Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers.

Info

Publication number
MA41742B1
MA41742B1 MA41742A MA41742A MA41742B1 MA 41742 B1 MA41742 B1 MA 41742B1 MA 41742 A MA41742 A MA 41742A MA 41742 A MA41742 A MA 41742A MA 41742 B1 MA41742 B1 MA 41742B1
Authority
MA
Morocco
Prior art keywords
cancers
determination
threshold
positivity
overexpression
Prior art date
Application number
MA41742A
Other languages
French (fr)
Other versions
MA41742A1 (en
Inventor
Benhassou Hassan Ait
Abdeladim MOUMEN
Hadi Hicham El
Original Assignee
Moroccan Foundation For Advanced Science Innovation And Res Mascir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moroccan Foundation For Advanced Science Innovation And Res Mascir filed Critical Moroccan Foundation For Advanced Science Innovation And Res Mascir
Priority to MA41742A priority Critical patent/MA41742B1/en
Priority to PCT/MA2018/050021 priority patent/WO2019132640A1/en
Publication of MA41742A1 publication Critical patent/MA41742A1/en
Publication of MA41742B1 publication Critical patent/MA41742B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode facile et pratique pour la détermination du seuil de positivité (threshold) pour la quantification de l’expression du gène her2 surexprimé dans le cas du cancer du sein, de l’estomac ainsi que dans d’autres types de cancers. La détection spécifique et la quantification des transcrits du gène her2 et les gènes de référence se font par la méthode de transcription inverse-pcr en temps réel (rtqpcr) en format multiplexe ou simplexe. Un échantillon sera considéré comme positif si son taux d’expression du gène her2 est supérieur au seuil de positivité calculé par la présente méthode.The present invention relates to an easy and practical method for the determination of the threshold of positivity (threshold) for the quantification of the expression of the her2 gene overexpressed in the case of breast and stomach cancer as well as in other types of cancer. cancers. The specific detection and quantification of the her2 gene transcripts and the reference genes is carried out by the real-time reverse-pcr transcription method (rtqpcr) in multiplex or simplex format. A sample will be considered positive if its level of expression of the her2 gene is greater than the positivity threshold calculated by this method.

MA41742A 2017-12-29 2017-12-29 Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers. MA41742B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MA41742A MA41742B1 (en) 2017-12-29 2017-12-29 Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers.
PCT/MA2018/050021 WO2019132640A1 (en) 2017-12-29 2018-12-28 Method for determining the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA41742A MA41742B1 (en) 2017-12-29 2017-12-29 Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers.

Publications (2)

Publication Number Publication Date
MA41742A1 MA41742A1 (en) 2019-08-30
MA41742B1 true MA41742B1 (en) 2020-02-28

Family

ID=65352067

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41742A MA41742B1 (en) 2017-12-29 2017-12-29 Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers.

Country Status (2)

Country Link
MA (1) MA41742B1 (en)
WO (1) WO2019132640A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA35294B1 (en) * 2012-12-27 2014-08-01 Mascir Moroccan Foundation For Advanced Science Innovation & Res Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment
KR101586846B1 (en) * 2014-02-25 2016-01-19 주식회사 옵티팜 A improved method for providing information for diagnosis of breast cancer and kit for diagnosis of breast cancer therefor
MA37437B1 (en) * 2014-10-17 2016-12-30 Mascir (Morrocan Found For Advanced Science Innovation & Research) Breast cancer diagnostic kit in qpcr multiplex reaction and its application in the evaluation of the status of the her2 protein and the choice of treatment

Also Published As

Publication number Publication date
MA41742A1 (en) 2019-08-30
WO2019132640A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
Yu et al. Long non‐coding RNA linc00261 suppresses gastric cancer progression via promoting Slug degradation
Biddle et al. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition
EP2420835A3 (en) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
NZ597363A (en) Prognosis prediction for colorectal cancer
IN2012DN00707A (en)
NZ586737A (en) Compositions and methods of detecting tiabs
Li et al. miR-451 regulates FoxO3 nuclear accumulation through Ywhaz in human colorectal cancer
WO2009019367A3 (en) Apolipoprotein ai assay method for the in vitro diagnosis of colorectal cancer
Ghedini et al. Shed HER2 extracellular domain in HER2‐mediated tumor growth and in trastuzumab susceptibility
US20120028252A1 (en) Human mena isoforms serve as markers of epithelial to mesenchymal transition and sensitivity to egfr inhibition in human cancer cells
Zhao et al. 14-3-3ζ/TGFβR1 promotes tumor metastasis in lung squamous cell carcinoma
RU2011123654A (en) N-CADGERIN: TARGET FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NORMAL FORMATIONS
MY145455A (en) Diagnostic biomolecule(s)
Volm et al. Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases
Peng et al. SUFU mediates EMT and Wnt/β-catenin signaling pathway activation promoted by miRNA-324-5p in human gastric cancer
MA37437B1 (en) Breast cancer diagnostic kit in qpcr multiplex reaction and its application in the evaluation of the status of the her2 protein and the choice of treatment
MA41742B1 (en) Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers.
Su et al. Research progress on exosomal proteins as diagnostic markers of gastric cancer
EP4180814A3 (en) Markers of endometrial cancer
Zhuo et al. Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1
Jiang et al. Decreased RGS6 expression is associated with poor prognosis in pancreatic cancer patients
WO2010149810A3 (en) In vitro method for the prognosis or prediction of the response in patients with rheumatoid arthritis treated with agents that recognize the cd20 membrane receptor in b lymphocytes
Lou et al. Prognostic significance of SOX-1 expression in human hepatocelluar cancer
Armada et al. Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAs’ involvement in cancer drug resistance
ES2906203T3 (en) Novel CIP2A variant and uses thereof